{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:12:30Z","timestamp":1789193550358,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:00:00Z","timestamp":1789171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:00:00Z","timestamp":1789171200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Key Program of National Natural Science Foundation of China","award":["U23A20465"],"award-info":[{"award-number":["U23A20465"]}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["23DZ2291400"],"award-info":[{"award-number":["23DZ2291400"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Nuclear Technology R&D Program","award":["HNKFHBZ202319"],"award-info":[{"award-number":["HNKFHBZ202319"]}]},{"name":"Shanghai Collaborative Innovation Project","award":["HCXBCY-2024-001"],"award-info":[{"award-number":["HCXBCY-2024-001"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272035"],"award-info":[{"award-number":["82272035"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["12275057"],"award-info":[{"award-number":["12275057"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanghai Oriental Talents Program Youth Project","award":["SSF828085"],"award-info":[{"award-number":["SSF828085"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"DOI":"10.1007\/s00259-026-08177-7","type":"journal-article","created":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T05:57:02Z","timestamp":1789192622000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic value and diagnostic performance of nectin-4-targeted [68Ga]Ga-FZ-NR-1 PET\/CT versus [18F]FDG in recurrent or metastatic triple-negative breast cancer"],"prefix":"10.1007","author":[{"given":"Ye","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongliang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2544-7522","authenticated-orcid":false,"given":"Shaoli","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,12]]},"reference":[{"key":"8177_CR1","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jama.2018.19323","volume":"321","author":"AG Waks","year":"2019","unstructured":"Waks AG, Winer EP. Breast Cancer Treatment: A Review. JAMA. 2019;321:288\u2013300. https:\/\/doi.org\/10.1001\/jama.2018.19323.","journal-title":"JAMA"},{"key":"8177_CR2","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","volume":"13","author":"G Bianchini","year":"2016","unstructured":"Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13:674\u201390. https:\/\/doi.org\/10.1038\/nrclinonc.2016.66.","journal-title":"Nat Rev Clin Oncol"},{"key":"8177_CR3","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3322\/caac.21863","volume":"74","author":"AN Giaquinto","year":"2024","unstructured":"Giaquinto AN, Sung H, Newman LA, Freedman RA, Smith RA, Star J, et al. Breast cancer statistics 2024. CA Cancer J Clin. 2024;74:477\u201395. https:\/\/doi.org\/10.3322\/caac.21863.","journal-title":"CA Cancer J Clin"},{"key":"8177_CR4","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ccell.2019.02.001","volume":"35","author":"YZ Jiang","year":"2019","unstructured":"Jiang YZ, Ma D, Suo C, Shi J, Xue M, Hu X, et al. Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies. Cancer Cell. 2019;35:428\u2013e405. https:\/\/doi.org\/10.1016\/j.ccell.2019.02.001.","journal-title":"Cancer Cell"},{"key":"8177_CR5","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41422-020-0375-9","volume":"31","author":"YZ Jiang","year":"2021","unstructured":"Jiang YZ, Liu Y, Xiao Y, Hu X, Jiang L, Zuo WJ, et al. Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial. Cell Res. 2021;31:178\u201386. https:\/\/doi.org\/10.1038\/s41422-020-0375-9.","journal-title":"Cell Res"},{"key":"8177_CR6","doi-asserted-by":"publisher","unstructured":"Chang HL, Schwettmann B, McArthur HL, Chan IS. Antibody-drug conjugates in breast cancer: overcoming resistance and boosting immune response. J Clin Invest. 2023;133. https:\/\/doi.org\/10.1172\/JCI172156.","DOI":"10.1172\/JCI172156"},{"key":"8177_CR7","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1093\/annonc\/mdw678","volume":"28","author":"MMR Cabaud","year":"2017","unstructured":"Cabaud MMR, Josselin O, Finetti E, Castellano P, Farina R. Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer. Ann Oncol. 2017;28:769\u201376. https:\/\/doi.org\/10.1093\/annonc\/mdw678.","journal-title":"Ann Oncol"},{"key":"8177_CR8","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.canlet.2016.02.049","volume":"375","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Liu S, Wang L, Wu Y, Hao J, Wang Z, et al. A novel PI3K\/AKT signaling axis mediates Nectin-4-induced gallbladder cancer cell proliferation, metastasis and tumor growth. Cancer Lett. 2016;375:179\u201389. https:\/\/doi.org\/10.1016\/j.canlet.2016.02.049.","journal-title":"Cancer Lett"},{"key":"8177_CR9","doi-asserted-by":"publisher","first-page":"217681","DOI":"10.1016\/j.canlet.2025.217681","volume":"622","author":"M Nikanjam","year":"2025","unstructured":"Nikanjam M, Perez-Granado J, Gramling M, Larvol B, Kurzrock R. Nectin-4 expression patterns and therapeutics in oncology. Cancer Lett. 2025;622:217681. https:\/\/doi.org\/10.1016\/j.canlet.2025.217681.","journal-title":"Cancer Lett"},{"key":"8177_CR10","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.annonc.2023.08.016","volume":"34","author":"JE Rosenberg","year":"2023","unstructured":"Rosenberg JE, Powles T, Sonpavde GP, Loriot Y, Duran I, Lee JL, et al. EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma. Ann Oncol. 2023;34:1047\u201354. https:\/\/doi.org\/10.1016\/j.annonc.2023.08.016.","journal-title":"Ann Oncol"},{"key":"8177_CR11","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/S1470-2045(25)00158-5","volume":"26","author":"S Gupta","year":"2025","unstructured":"Gupta S, Loriot Y, Van der Heijden MS, Bedke J, Valderrama BP, Kikuchi E, et al. Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study. Lancet Oncol. 2025;26:795\u2013805. https:\/\/doi.org\/10.1016\/S1470-2045(25)00158-5.","journal-title":"Lancet Oncol"},{"key":"8177_CR12","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.annonc.2025.04.009","volume":"36","author":"J Zhang","year":"2025","unstructured":"Zhang J, Liu R, Wang S, Feng Z, Yang H, Gao S, et al. Bulumtatug Fuvedotin (BFv, 9MW2821), a next-generation Nectin-4 targeting antibody-drug conjugate, in patients with advanced solid tumors: a first-in-human, open-label, multicenter, phase I\/II study. Ann Oncol. 2025;36:934\u201343. https:\/\/doi.org\/10.1016\/j.annonc.2025.04.009.","journal-title":"Ann Oncol"},{"key":"8177_CR13","doi-asserted-by":"publisher","unstructured":"Zhong R, Yan M, Wang Q, Hong H, Zhang Y, Hu M, et al. SHR-A2102, a nectin-4 directed antibody-drug conjugate, in patients with pretreated advanced solid tumours: a multicentre, single-arm, phase 1 trial. Lancet Oncol. 2026;27:1146\u201357. https:\/\/doi.org\/10.1016\/S1470-2045(26)00238-X.","DOI":"10.1016\/S1470-2045(26)00238-X"},{"key":"8177_CR14","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3322\/caac.21705","volume":"72","author":"P Tarantino","year":"2022","unstructured":"Tarantino P, Carmagnani Pestana R, Corti C, Modi S, Bardia A, Tolaney SM, et al. Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies. CA Cancer J Clin. 2022;72:165\u201382. https:\/\/doi.org\/10.3322\/caac.21705.","journal-title":"CA Cancer J Clin"},{"key":"8177_CR15","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","volume":"18","author":"JZ Drago","year":"2021","unstructured":"Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol. 2021;18:327\u201344. https:\/\/doi.org\/10.1038\/s41571-021-00470-8.","journal-title":"Nat Rev Clin Oncol"},{"key":"8177_CR16","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.2967\/jnumed.123.266830","volume":"65","author":"J Zhang","year":"2024","unstructured":"Zhang J, Duan X, Chen X, Zhang Z, Sun H, Shou J, et al. Translational PET Imaging of Nectin-4 Expression in Multiple Different Cancers with (68)Ga-N188. J Nucl Med. 2024;65:S12\u20138. https:\/\/doi.org\/10.2967\/jnumed.123.266830.","journal-title":"J Nucl Med"},{"key":"8177_CR17","doi-asserted-by":"publisher","first-page":"592","DOI":"10.2967\/jnumed.124.268387","volume":"66","author":"H Babeker","year":"2025","unstructured":"Babeker H, Njotu FN, Pougoue Ketchemen J, Monzer A, Tikum AF, Doroudi A, et al. (225)Ac\/(89)Zr-Labeled N4MU01 Radioimmunoconjugates as Theranostics Against Nectin-4-Positive Triple-Negative Breast Cancer. J Nucl Med. 2025;66:592\u20138. https:\/\/doi.org\/10.2967\/jnumed.124.268387.","journal-title":"J Nucl Med"},{"key":"8177_CR18","doi-asserted-by":"publisher","first-page":"473","DOI":"10.2967\/jnumed.124.269024","volume":"66","author":"L Sun","year":"2025","unstructured":"Sun L, Sun Y, Zuo K, Fan L, Wang X, Zhang J, et al. Pilot Study of Nectin-4-Targeted PET Imaging Agent (68)Ga-FZ-NR-1 in Triple-Negative Breast Cancer from Bench to First-in-Human. J Nucl Med. 2025;66:473\u20139. https:\/\/doi.org\/10.2967\/jnumed.124.269024.","journal-title":"J Nucl Med"},{"key":"8177_CR19","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.1007\/s00259-025-07609-0","volume":"53","author":"C Jiang","year":"2026","unstructured":"Jiang C, Wei M, Li P, Hu S, Xu X, Li J, et al. A pilot study of nectin-4-targeted radioligand [(68)Ga]Ga-FZNR-1 in patients with pancreatic ductal adenocarcinoma: head-to-head comparison with [(18)F]-FDG. Eur J Nucl Med Mol Imaging. 2026;53:2362\u201374. https:\/\/doi.org\/10.1007\/s00259-025-07609-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8177_CR20","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"key":"8177_CR21","doi-asserted-by":"publisher","first-page":"eady1111","DOI":"10.1126\/sciadv.ady1111","volume":"12","author":"A Mishra","year":"2026","unstructured":"Mishra A, Sharma AK, Gupta K, Banka DS, Johnson BA, Hoffman-Censits J, et al. Nectin-4 PET for predicting enfortumab vedotin dose-response in urothelial carcinoma. Sci Adv. 2026;12:eady1111. https:\/\/doi.org\/10.1126\/sciadv.ady1111.","journal-title":"Sci Adv"},{"key":"8177_CR22","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1158\/1078-0432.CCR-22-1764","volume":"29","author":"N Klumper","year":"2023","unstructured":"Klumper N, Ralser DJ, Ellinger J, Roghmann F, Albrecht J, Below E, et al. Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance. Clin Cancer Res. 2023;29:1496\u2013505. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-1764.","journal-title":"Clin Cancer Res"},{"key":"8177_CR23","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1200\/JCO.23.01983","volume":"42","author":"N Klumper","year":"2024","unstructured":"Klumper N, Tran NK, Zschabitz S, Hahn O, Buttner T, Roghmann F, et al. NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer. J Clin Oncol. 2024;42:2446\u201355. https:\/\/doi.org\/10.1200\/JCO.23.01983.","journal-title":"J Clin Oncol"},{"key":"8177_CR24","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s12938-023-01173-0","volume":"22","author":"H Jonsson","year":"2023","unstructured":"Jonsson H, Ahlstrom H, Kullberg J. Spatial mapping of tumor heterogeneity in whole-body PET-CT: a feasibility study. Biomed Eng Online. 2023;22:110. https:\/\/doi.org\/10.1186\/s12938-023-01173-0.","journal-title":"Biomed Eng Online"},{"key":"8177_CR25","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/ncponc1041","volume":"5","author":"WA Weber","year":"2008","unstructured":"Weber WA, Grosu AL, Czernin J. Technology Insight: advances in molecular imaging and an appraisal of PET\/CT scanning. Nat Clin Pract Oncol. 2008;5:160\u201370. https:\/\/doi.org\/10.1038\/ncponc1041.","journal-title":"Nat Clin Pract Oncol"},{"key":"8177_CR26","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1113205","volume":"366","author":"M Gerlinger","year":"2012","unstructured":"Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder D, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366:883\u201392. https:\/\/doi.org\/10.1056\/NEJMoa1113205.","journal-title":"N Engl J Med"},{"key":"8177_CR27","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1158\/1078-0432.CCR-25-0160","volume":"31","author":"L Zhao","year":"2025","unstructured":"Zhao L, Pang Y, Ding Y, Chen J, Fang J, Yu L, et al. 68Ga-NK224 PET\/CT for Noninvasive Evaluation of PD-L1 Expression and Intertumor Heterogeneity: A Translational Exploratory Study. Clin Cancer Res. 2025;31:2989\u20133001. https:\/\/doi.org\/10.1158\/1078-0432.CCR-25-0160.","journal-title":"Clin Cancer Res"},{"key":"8177_CR28","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1126\/science.1160809","volume":"324","author":"MG Vander Heiden","year":"2009","unstructured":"Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324:1029\u201333. https:\/\/doi.org\/10.1126\/science.1160809.","journal-title":"Science"},{"key":"8177_CR29","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1148\/radiographics.19.1.g99ja0761","volume":"19","author":"PD Shreve","year":"1999","unstructured":"Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics. 1999;19:61\u201377. https:\/\/doi.org\/10.1148\/radiographics.19.1.g99ja0761. quiz 150-1.","journal-title":"Radiographics"},{"key":"8177_CR30","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.2967\/jnumed.106.037689","volume":"48","author":"W Chen","year":"2007","unstructured":"Chen W. Clinical applications of PET in brain tumors. J Nucl Med. 2007;48:1468\u201381. https:\/\/doi.org\/10.2967\/jnumed.106.037689.","journal-title":"J Nucl Med"},{"key":"8177_CR31","doi-asserted-by":"publisher","first-page":"365","DOI":"10.2967\/jnumed.123.266556","volume":"65","author":"B Gu","year":"2024","unstructured":"Gu B, Yang Z, Du X, Xu X, Ou X, Xia Z, et al. Imaging of Tumor Stroma Using (68)Ga-FAPI PET\/CT to Improve Diagnostic Accuracy of Primary Tumors in Head and Neck Cancer of Unknown Primary: A Comparative Imaging Trial. J Nucl Med. 2024;65:365\u201371. https:\/\/doi.org\/10.2967\/jnumed.123.266556.","journal-title":"J Nucl Med"},{"key":"8177_CR32","doi-asserted-by":"publisher","unstructured":"Chen H, Zhao L, Pang Y, Shi J, Gao H, Sun Y, et al. 68Ga-MY6349 PET\/CT imaging to assess Trop2 expression in multiple types of cancer. J Clin Invest. 2024;135. https:\/\/doi.org\/10.1172\/JCI185408.","DOI":"10.1172\/JCI185408"},{"key":"8177_CR33","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1007\/s00259-025-07628-x","volume":"53","author":"S Zang","year":"2026","unstructured":"Zang S, Meng Q, Li X, Guo T, Zhang L, Zhao Z, et al. Fully automated volumetric assessment of tumor burden using artificial intelligence on (68)Ga-PSMA-11 PET predicts survival after (177)Lu-PSMA therapy in metastatic Castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2026;53:1913\u201326. https:\/\/doi.org\/10.1007\/s00259-025-07628-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8177_CR34","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1016\/S1470-2045(25)00339-0","volume":"26","author":"L Emmett","year":"2025","unstructured":"Emmett L, Papa N, Subramaniam S, Crumbaker M, Nguyen A, Joshua AM, et al. Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2025;26:1168\u201377. https:\/\/doi.org\/10.1016\/S1470-2045(25)00339-0.","journal-title":"Lancet Oncol"},{"key":"8177_CR35","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1007\/s00259-025-07622-3","volume":"53","author":"MT Tatoglu","year":"2026","unstructured":"Tatoglu MT, Okten IN, Ibisoglu E, Soylemez Akkurt T, Tozan E, Tatoglu FY, et al. Integrating PET\/CT-derived heterogeneity indices and composite risk scores improves prognostic stratification in breast cancer. Eur J Nucl Med Mol Imaging. 2026;53:2439\u201354. https:\/\/doi.org\/10.1007\/s00259-025-07622-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8177_CR36","doi-asserted-by":"publisher","unstructured":"Bouron C, Mathie C, Seegers V, Morel O, Jezequel P, Lasla H, et al. Prognostic value of metabolic, Volumetric and textural parameters of baseline [(18)F]FDG PET\/CT in early triple-negative breast cancer. Cancers (Basel). 2022;14. https:\/\/doi.org\/10.3390\/cancers14030637.","DOI":"10.3390\/cancers14030637"},{"key":"8177_CR37","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.2967\/jnumed.111.098087","volume":"53","author":"T Huang","year":"2012","unstructured":"Huang T, Civelek AC, Li J, Jiang H, Ng CK, Postel GC, et al. Tumor microenvironment-dependent 18F-FDG, 18F-fluorothymidine, and 18F-misonidazole uptake: a pilot study in mouse models of human non-small cell lung cancer. J Nucl Med. 2012;53:1262\u20138. https:\/\/doi.org\/10.2967\/jnumed.111.098087.","journal-title":"J Nucl Med"},{"key":"8177_CR38","doi-asserted-by":"publisher","first-page":"565","DOI":"10.2967\/jnumed.124.267809","volume":"66","author":"V Santoro-Fernandes","year":"2025","unstructured":"Santoro-Fernandes V, Schott B, Weisman AJ, Lokre O, Cho SY, Perlman SB, et al. Full-Body Tumor Response Heterogeneity of Metastatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radiopharmaceutical Therapy. J Nucl Med. 2025;66:565\u201371. https:\/\/doi.org\/10.2967\/jnumed.124.267809.","journal-title":"J Nucl Med"},{"key":"8177_CR39","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.2967\/jnumed.120.260836","volume":"62","author":"K Michalski","year":"2021","unstructured":"Michalski K, Klein C, Brueggemann T, Meyer PT, Jilg CA, Ruf J. Assessing Response to [(177)Lu]PSMA Radioligand Therapy using modified PSMA PET Progression Criteria. J Nucl Med. 2021;62:1741\u20136. https:\/\/doi.org\/10.2967\/jnumed.120.260836.","journal-title":"J Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08177-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-08177-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08177-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T05:57:03Z","timestamp":1789192623000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-08177-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,12]]},"references-count":39,"alternative-id":["8177"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-08177-7","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,12]]},"assertion":[{"value":"17 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures involving animals and human participants were carried out in accordance with the ethical standards of the Ethics Committee of Fudan University Shanghai Cancer Center and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors affirm that human research participants provided informed consent for publication.","order":3,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or nonfinancial interests to disclose.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}